http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-07-03T12:43:26.175Z

http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

cyramza r as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastro esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinum containing chemotherapy 1 1 in combination with docetaxel for treatment of metastatic non small cell lung cancer with disease progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza 1 2 in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 1 3 as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 4 ng ml and have been treated with sorafenib 1 4 cyramza r cyramza in combination with docetaxel is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with disease progression on or after platinum based chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine

Leoni Bücken

2021-07-03T12:43:26.175Z

http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_3908 DOID_3908

Leoni Bücken

2021-07-03T12:43:26.175Z

http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-07-03T12:43:26.175Z

http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB05578 drugbank:DB05578

Leoni Bücken

2021-07-03T12:43:26.175Z

http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-07-03T12:43:26.175Z

http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-07-03T12:43:26.175Z

http://purl.org/np/RAmIAR0YhB... RAmIAR0YhB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-07-03T12:43:26.175Z